Navigation Links
Mylan's Matrix Receives Tentative FDA Approval Under PEPFAR for Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets
Date:9/16/2009

PITTSBURGH, Sept. 16 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its privately held Indian subsidiary, Matrix Laboratories Limited, has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets, 600 mg/300 mg/300 mg.

Mylan's product represents the first-ever fixed-dose combination of Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate and now provides Matrix with numerous Tenofovir combination product opportunities. This new drug adds to the Matrix portfolio of important treatments for HIV/AIDS. The product may be used for either first- or second-line treatment in adults. People use second-line therapies if and when they develop resistance to initially prescribed treatments.

Mylan President Heather Bresch said: "This product represents yet another important advance in our continuing fight against the global epidemic of HIV/AIDS. By combining three antiretroviral (ARV) products into a once-daily dose, we can dramatically improve the quality of care for people living with HIV/AIDS in emerging markets. Lower pill burden also increases the likelihood that patients adhere to treatment. This innovation also adds another affordable option to our large and rapidly growing portfolio of life-sustaining ARV products."

The FDA's tentative approval under PEPFAR means that Matrix's product meets all of the agency's manufacturing quality, safety and efficacy standards. Although existing patents or exclusivity prevent its marketing in the U.S., the product will be eligible for purchase outside the U.S. in many developing countries.

Matrix's wide range of AR
'/>"/>

SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Scientific Journal Gene Therapy Reports That Cardiums Gene Activated Matrix Technology Accelerates Periodontal Tissue Regeneration
2. Matrixx Initiatives, Inc. Names William J. Hemelt President, CEO and Board Member
3. Matrixx Initiatives to Webcast 2009 Annual Stockholder Meeting Wednesday, August 26, 2009
4. Mylans Matrix Receives First and Only Tentative FDA Approval Under PEPFAR for Generic Version of Atripla(R) HIV Treatment
5. Sigma-Aldrich Offers Customizable Synthetic Extracellular Matrix for Stem Cell Research
6. Matrixx Initiatives, Inc. Sets Time for Discussion of First Quarter Fiscal 2010 Financial Results
7. MedInsights Partners With myMatrixx(TM) for Workers Compensation Pharmacy Benefit Management
8. Matrixx Initiatives Confirms Voluntary Recall of Zicam Cold Remedy Nasal Gel, Zicam Cold Remedy Gel Swabs
9. Matrixx Initiatives, Inc. Sets Time for Discussion of Recent FDA Action
10. Matrixx Initiatives Voluntarily Withdraws Zicam Cold Remedy Swabs, Zicam Cold Remedy Nasal Gel
11. Matrixx Initiatives, Inc. Received a Warning Letter From the Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... UT (PRWEB) August 28, 2014 CMMI (Center ... coordination and integration of care to address patient needs. What ... quality of care outcomes (with more provider accountability) and reduce ... all the people involved in the care of a patient ... figure out how to distribute it. If it sounds complicated, ...
(Date:8/28/2014)... August 28, 2014 GreenRushReview.com, a ... recently launched a “Video” section located at ... information on various cannabis companies in video format. ... an assortment of news clips, interviews, and other ... A portion of the videos can also be ...
(Date:8/28/2014)... August 28, 2014 Genetic testing ... throughout the world, with large reference laboratories as ... laboratories differ with regard to the genetic variants ... payers may struggle to find the most appropriate ... help clients sort through these differences, Hayes, Inc. ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 On September ... interview Stephen Isaacs, the chairperson, president and CEO of ... Meet the Mesothelioma Experts live broadcast. The ... director and mesothelioma expert nurse practitioner, Mary Hesdorffer, ... will be Aduro BioTech’s experimental therapy for malignant pleural ...
(Date:8/28/2014)... The Foundation for Women’s Cancer ... by alerting women to the link between obesity and ... of endometrial cancer. , Endometrial cancer is the ... cancer. More than 52,600 will learn of a diagnosis ... with weight management challenges to know the early warning ...
Breaking Medicine News(10 mins):Health News:Med-Certification.com Expects Industry "Hiccups" with New Models for Patient Care and Reimbursement 2Health News:Emerging Cannabis Industry Website GreenRushReview.com Adds a Featured Video Section to Cover Marijuana Business Sector News 2Health News:Emerging Cannabis Industry Website GreenRushReview.com Adds a Featured Video Section to Cover Marijuana Business Sector News 3Health News:Hayes, Inc. Unveils Laboratory Comparison Tables for GTE Clients 2Health News:New Clinical Trial: Using the Listeria Virus to Fight Mesothelioma 2Health News:New Clinical Trial: Using the Listeria Virus to Fight Mesothelioma 3Health News:Foundation for Women's Cancer Alerts Women to Link Between Obesity and Endometrial Cancer 2
... A study published in the October 15 issue ... the Cleveland Adolescent Sleepiness Questionnaire (CASQ), a new self-completed ... The study, led by James C. Spilsbury, PhD, of ... Ohio, focused on a subsample of 411 adolescents between ...
... 11:30 am EDT, TEL AVIV, Israel, October 15 ... that it has signed,an agreement to acquire 100% of ... Blessing Biotech GmbH (together the "Gewurzmuller,Group"), in consideration for ... The Company will be hosting a conference call ...
... Island Hospital and Brown University researchers reported that 18 percent ... initial psychiatric clearance for the surgery. The study is the ... for surgery, and the largest to determine the percentage of ... exclusion. It was published in the October edition of the ...
... of ills such as heart disease , , SUNDAY, ... collections of genetic and clinical data available free to ... Institutes of Health. , The Web-based SHARe (SNP Health ... from a number of large population-based studies, starting with ...
... breathing disorder, arterial trouble , FRIDAY, Oct. 12 (HealthDay ... airway pressure (CPAP) to treat people with obstructive sleep ... of the arteries -- within months, a new study ... of a direct link between obstructive sleep apnea and ...
... BEACH, Calif., Oct. 12 History,will be written if ... Act during a vote scheduled for next week. It ... law regarding swimming pool and spa safety.,The National Drowning ... but with wording similar to HR 1721 passed on ...
Cached Medicine News:Health News:New tool to assess excessive daytime sleepiness in adolescents published in JCSM 2Health News:Frutarom Gewurzmuller and Blessing Biotech Acquisition Conference Call Scheduled for Monday, October 15, 2007 2Health News:1 in 5 bariatric surgery candidates not psychologically cleared for surgery 2Health News:U.S. Unveils Database of Genetic, Clinical Research 2Health News:Sleep Apnea Treatment Helps Stave Off Heart Disease 2Health News:NDPA Urges Passage of Historic Pool Bill 2
(Date:8/27/2014)... 28, 2014 China Nepstar Chain Drugstore ... "Company"), a leading retail drugstore chain in China ... today announced its unaudited financial results for the ... HighlightsFor the quarter ended June 30, 2014: , ... compared to RMB638.8 million in the second quarter ...
(Date:8/27/2014)... LONDON , Aug. 27, 2014 /PRNewswire/ ... research report: Co-development Terms & ... https://www.reportbuyer.com/product/2276221/Co-development-Terms--Agreements-in-Pharma-Biotech-and-Diagnostics.html The ... and Diagnostics report provides comprehensive understanding and ... agreements entered into by the worlds leading ...
(Date:8/27/2014)... About 8 million Americans have peripheral arterial ... fatty plaque in the arteries, according to recent statistics. ... in incidences of diabetes and obesity, the Society ... Arterial RevascularizatioN (LEARN) meeting, Oct. 9–11 in ... residents and fellows will be able to gain state-of-the-art ...
Breaking Medicine Technology:China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 10China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 11Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 2Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 3Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 4Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 5Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 6Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 7LEARN to Treat Peripheral Arterial Disease Patients 2LEARN to Treat Peripheral Arterial Disease Patients 3
... ANGELES and OAKLAND, Calif., March 15, 2012  With the ... community clinics face unprecedented challenges. To flourish, clinics now ... To facilitate this change in strategy, ... Finance Fund (NFF), announces the California Catalyst Fund ...
... Inc., a clinical-stage biopharmaceutical company developing novel oncology therapeutics ... bulk, today announced that Kevin Buchi has joined its ... Executive Officer of Cephalon, Inc. through its $6.8 billion ... ) in October 2011, Mr. Buchi has served as ...
Cached Medicine Technology:New Restructuring Fund Launches for California Community Clinics 2Stemline Therapeutics Appoints Kevin Buchi, Former CEO of Cephalon, to Its Board of Directors 2
... the semi-quantitative determination of specific IgA autoantibodies ... of the anti-Gliadin IgA assay can be ... of diseases associated with elevated levels of ... these autoantibodies are one indicator in a ...
... ADVIA Urinalysis WorkCell System - A ... tests per hour, with true load-and-go ... of Clinitek Atlas and UF-100 for ... regarded systems working together deliver utmost ...
... (EIA) test kit is to be used ... in human serum during the second half ... (unconjugated) procedure is an enzyme immunoassay which ... binding. In the procedure, estriol is ...
Assay uses highly specific rabbit anti-estriol antibody reparation - negligible cross-reactivity with other estrogen metabolites. Excellent assay precision and reproducibility. Superior sensitivity ...
Medicine Products: